Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Myocardial Ischemia - Overview
Myocardial Ischemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Myocardial Ischemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Myocardial Ischemia - Companies Involved in Therapeutics Development
Angionetics Inc
AstraZeneca Plc
Bayer AG
Cadrock Pty Ltd
Caladrius Biosciences Inc
Cellmid Ltd
Chrysalis BioTherapeutics Inc
CohBar Inc
Everon Biosciences Inc
Guangzhou Magpie Pharmaceutical Co Ltd
Lixte Biotechnology Holdings Inc
NoNO Inc
Omniox Inc
Q BioMed Inc
Symvivo Inc
Vasade Biosciences Inc
Myocardial Ischemia - Drug Profiles
alferminogene tadenovec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-8601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
azithromycin + doxycycline + rifabutin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-606583 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLBS-14 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CMK-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DT-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Myocardial Ischemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Humanin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LB-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MAN-04 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMX-4.80P - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PMC-6 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombint Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rusalatide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sirolimus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Myocardial Ischemia Reperfusion Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize TRPM7 for Oncology, Ophthalmology, Cardiovascular and Central nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Myocardial Ischemia - Dormant Projects
Myocardial Ischemia - Discontinued Products
Myocardial Ischemia - Product Development Milestones
Featured News & Press Releases
Feb 20, 2019: Phase 1 data published in ture Communications show potential of mR encoding VEGF-A as a regenerative therapeutic
Jan 09, 2017: Angionetics Research Head Authors Scientific American Article on Therapeutic Angiogenesis as Potential New Treatment Approach for Ischemic Heart Disease
Sep 12, 2016: Angionetics’ Generx Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Corory Artery Disease
May 11, 2015: Angionetics Presents At 2015 Annual Marcum MicroCap Conference On Business And Generx Clinical Development Activities
Jan 27, 2015: Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum
Sep 03, 2014: Taxus Cardium to Present at the Rodman & Renshaw 16th Annual Global Investment Conference in New York City
Aug 13, 2014: Taxus Cardium Announces Biological and Clinical Advances in Angiogenic Gene Therapy for Heart Disease in Jourl of Cardiovascular Pharmacology
Jun 12, 2014: Cardium To Announce Interim Results Of Generx Angiogenic Gene Therapy Phase 3 Clinical Study At The 2014 BIO Intertiol Convention
Jan 27, 2014: Cardium Announces Strategic Focus On Advanced Regenerative Therapeutics Based On Generx Clinical Findings
May 02, 2013: Cardium Therapeutics Announces Publication Of Data On Generx In Jourl Molecular Therapy
Nov 19, 2012: Cardium Therapeutics Announces Patent Award For Rights To Cardiovascular Gene Therapy For Treatment Of Heart Disease
Oct 25, 2012: Cytori Announces Japanese Approval For Clinical Studies Of Cardiovascular And Chronic Liver Disease Cell Therapy
Mar 20, 2012: Cardium Therapeutics Initiates Generx Phase III Clinical Registration Study
Feb 28, 2012: Baxter Initiates Phase III Adult Stem Cell Clinical Trial For Chronic Cardiac Condition
Jun 15, 2011: Cardium Therapeutics’s Generx D-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance For Phase III Registration Clinical Study For Corory Artery Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Myocardial Ischemia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020


List of Tables


Number of Products under Development for Myocardial Ischemia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Myocardial Ischemia - Pipeline by Angionetics Inc, H1 2020
Myocardial Ischemia - Pipeline by AstraZeneca Plc, H1 2020
Myocardial Ischemia - Pipeline by Bayer AG, H1 2020
Myocardial Ischemia - Pipeline by Cadrock Pty Ltd, H1 2020
Myocardial Ischemia - Pipeline by Caladrius Biosciences Inc, H1 2020
Myocardial Ischemia - Pipeline by Cellmid Ltd, H1 2020
Myocardial Ischemia - Pipeline by Chrysalis BioTherapeutics Inc, H1 2020
Myocardial Ischemia - Pipeline by CohBar Inc, H1 2020
Myocardial Ischemia - Pipeline by Everon Biosciences Inc, H1 2020
Myocardial Ischemia - Pipeline by Guangzhou Magpie Pharmaceutical Co Ltd, H1 2020
Myocardial Ischemia - Pipeline by Lixte Biotechnology Holdings Inc, H1 2020
Myocardial Ischemia - Pipeline by NoNO Inc, H1 2020
Myocardial Ischemia - Pipeline by Omniox Inc, H1 2020
Myocardial Ischemia - Pipeline by Q BioMed Inc, H1 2020
Myocardial Ischemia - Pipeline by Symvivo Inc, H1 2020
Myocardial Ischemia - Pipeline by Vasade Biosciences Inc, H1 2020
Myocardial Ischemia - Dormant Projects, H1 2020
Myocardial Ischemia - Dormant Projects, H1 2020 (Contd..1), H1 2020
Myocardial Ischemia - Discontinued Products, H1 2020